Page last updated: 2024-10-24

phosphate ion transport

Definition

Target type: biologicalprocess

The directed movement of phosphate ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. [GOC:krc]

Phosphate ion transport is a fundamental biological process that plays a crucial role in numerous cellular functions. It involves the movement of inorganic phosphate (Pi) across cell membranes, ensuring the appropriate levels of Pi are maintained within the cell and its various compartments. This intricate process is mediated by a diverse array of specialized membrane transporters, each exhibiting unique characteristics and regulatory mechanisms.

Pi is an essential nutrient for all living organisms, serving as a building block for essential biomolecules such as ATP, nucleic acids, and phospholipids. The precise control of Pi levels is crucial for maintaining cellular energy metabolism, signaling pathways, and structural integrity.

The transport of Pi across cell membranes can occur via passive diffusion, facilitated diffusion, or active transport, depending on the specific transporter and the concentration gradient of Pi across the membrane.

Passive diffusion occurs when Pi moves down its concentration gradient, from an area of high concentration to an area of low concentration, without requiring any energy input. This mode of transport is generally less significant for Pi uptake, as intracellular Pi concentrations are typically lower than extracellular concentrations.

Facilitated diffusion involves the movement of Pi across the membrane with the assistance of a membrane transporter protein. These transporters bind to Pi and facilitate its movement across the membrane without requiring energy input. However, they still rely on the concentration gradient of Pi for transport.

Active transport, on the other hand, requires energy expenditure to move Pi against its concentration gradient. This type of transport is essential for maintaining high intracellular Pi concentrations, even when extracellular Pi levels are low. Active transport is often coupled to other energy-yielding processes, such as the movement of ions or the hydrolysis of ATP.

The specific mechanisms and regulatory pathways of phosphate ion transport vary depending on the cell type and its physiological needs. For instance, in the intestines, Pi uptake is crucial for absorbing dietary Pi, while in the kidneys, Pi reabsorption is essential for maintaining Pi homeostasis.

The intricate interplay between various transporter proteins, signaling pathways, and regulatory mechanisms ensures the precise control of Pi levels within the cell and its various compartments. This tightly regulated process is essential for maintaining cellular function and overall organismal health. The disruption of Pi transport can lead to various diseases, including rickets, osteomalacia, and renal phosphate wasting.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Sodium-dependent phosphate transport protein 2BA sodium-dependent phosphate transport protein 2B that is encoded in the genome of human. [PRO:DNx, UniProtKB:O95436]Homo sapiens (human)

Compounds (2)

CompoundDefinitionClassesRoles
crizotinibcrizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
pf-06463922lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.

lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein
aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor